Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30121% above fair value
$23.04−0.92 (-3.84%)
Close on Nov 13, 2026Market cap $6.51BP/E –Yield –
Caris Life Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Caris Life Sciences's ebitda for the twelve months ending Sep 30, 2026 was $162.39M. For fiscal 2025 it was $67.73M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.73M | – |
| FY2024 | Dec 31, 2024 | -$208.21M | – |
| FY2023 | Dec 31, 2023 | -$270.55M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.92M | -31.0% |
| Q2 FY2026 | Jun 30, 2026 | $33.43M | – |
| Q1 FY2026 | Mar 31, 2026 | $10.35M | – |
| Q4 FY2025 | Dec 31, 2025 | $92.70M | – |
| Q3 FY2025 | Sep 30, 2025 | $37.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$50.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$50.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.41M | – |
See a number that looks wrong?